MediciNova, Inc. (MNOV)
After hours:
| Previous Close | 1.3100 |
| Open | 1.4200 |
| Bid | 1.0600 x 200 |
| Ask | 1.8100 x 200 |
| Day's Range | 1.4001 - 1.5000 |
| 52 Week Range | 1.1200 - 2.4500 |
| Volume | |
| Avg. Volume | 23,922 |
| Market Cap | 73.569M |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1600 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.00 |
- Zacks Small Cap Research
MNOV: Phase 3 ALS Readout in 2025…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Phase 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is currently evaluating MN-166 (ibudilast) in a Phase 3 clinical trial for amyotrophic lateral sclerosis (ALS). The trial initiated in 2019 and, if successful, results from this trial are expected to support a New Drug Application (NDA) for MN-166 in ALS. A
GlobeNewswireMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for?New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast
Simply Wall St.MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...
